Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolynovoCALZF 74 Net Cash per Share is $-0.01 as of Jun. 2026. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $1.68 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 296 Medical Devices & Instruments companies, Polynovo ranks worse than 337837.5% on this metric.
The historical rank and industry rank for Polynovo's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Polynovo was 245.00. The lowest was 21.00. And the median was 40.63.
CALZF's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.105 * Ranked among companies with meaningful Price-to-Net-Cash only.
Polynovo (OTCPK:CALZF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Polynovo Net Cash per Share Related Terms
Polynovo Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Polynovo's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CALZF vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, Polynovo's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Polynovo's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Polynovo's Net Cash per Share for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a Net Cash per Share of $-0.01 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #999999 out of 296 companies in the Medical Devices & Instruments industry.
Is Polynovo's Net Cash per Share too high?
Polynovo's current Net Cash per Share is $-0.01. Based on the distribution chart, Polynovo ranks #999999 out of 296 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #999999 out of 296 companies for Net Cash per Share. This places Polynovo in the lower half of its industry. The industry median Net Cash per Share is 9.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.11, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Net Cash per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.68, compared to a current price of $0.75 — trading 55.2% below its estimated fair value. The current Net Cash per Share is $-0.01. Polynovo's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Polynovo (CALZF), the current Net Cash per Share is $-0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.75 is trading 55.2% below its estimated GF Value™ of $1.68.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Net Cash per Share: $-0.01
GF Value™: $1.68 vs. price of $0.75 (55.2% below fair value)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
